Zynquista was not approved by the FDA; Complete Response Letter suggests the FDA is weighing safety concerns of the SGLT-1/2 dual inhibitor for type 1 diabetes Continue Reading »
You can help more people with diabetes
The latest research in type 1 diabetes, type 2 diabetes, prediabetes, and beyond. Here you’ll find information on experimental therapies, new data and results, and scientific findings.
Zynquista was not approved by the FDA; Complete Response Letter suggests the FDA is weighing safety concerns of the SGLT-1/2 dual inhibitor for type 1 diabetes Continue Reading »
Learn more about JDRF’s efforts in finding a cure for type 1 diabetes and read highlights from experts’ discussions on SGLT inhibitors in type 1 and Beyond A1C Continue Reading »
From clinical expertise and personal experience as a type 1, Dr. Sherr shares valuable (and exciting) perspectives on diabetes treatments. Continue Reading »
Farxiga and Zynquista are recommended for approval for people with type 1 diabetes in Europe with emphasis on DKA safety; EMA approval likely in coming months and hope for approval in US Continue Reading »
T1D Exchange Registry data reveals only 17% of youth and 21% of adults are meeting A1C goals, even though more are on pumps and CGM Continue Reading »
FDA updates Invokana label – the type 2 diabetes therapy now improves heart health in type 2’s with established heart disease in addition to glucose lowering Continue Reading »
Recently announced results from the REWIND and EMPRISE studies show heart protective effects of GLP1-agonist Trulicity and SGLT-2 inhibitor Jardiance in people with and without established heart disease Continue Reading »
Surprising study findings from a look at refrigerator temperatures and the risk posed to insulin quality; plus, a guide to safe insulin storage and Med Angel’s very cool temp sensor Continue Reading »
Need help? Search free and reduced cost services like medical care, food, housing, and more in your area.
